Natixis Advisors
CORT icon

Natixis Advisors’s Corcept Therapeutics CORT Stock Holding History

Natixis Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.38M Buy
50,392
+24,758
+97% +$1.49M ﹤0.01% 956
2026
Q1 		$1.03M Sell
25,634
-10,753
-30% -$402K ﹤0.01% 1346
2025
Q4 		$1.27M Sell
36,387
-5,701
-14% -$448K ﹤0.01% 1188
2025
Q3 		$3.5M Sell
42,088
-68
-0.2% -$4.92K 0.01% 943
2025
Q2 		$3.09M Buy
42,156
+2,426
+6% +$176K ﹤0.01% 965
2025
Q1 		$4.54M Buy
39,730
+7,607
+24% +$463K 0.01% 839
2024
Q4 		$1.62M Buy
32,123
+3,979
+14% +$208K ﹤0.01% 1165
2024
Q3 		$1.3M Buy
28,144
+7,484
+36% +$266K ﹤0.01% 1222
2024
Q2 		$671K Buy
20,660
+2,854
+16% +$78.2K ﹤0.01% 1367
2024
Q1 		$449K Sell
17,806
-4,101
-19% -$96.9K ﹤0.01% 1418
2023
Q4 		$711K Sell
21,907
-1,886
-8% -$51.8K ﹤0.01% 1312
2023
Q3 		$648K Buy
23,793
+4,921
+26% +$142K ﹤0.01% 1294
2023
Q2 		$420K Sell
18,872
-1,615
-8% -$37.2K ﹤0.01% 1372
2023
Q1 		$444K Buy
20,487
+5,710
+39% +$125K ﹤0.01% 1337
2022
Q4 		$300K Sell
14,777
-4,123
-22% -$103K ﹤0.01% 1392
2022
Q3 		$485K Buy
18,900
+2,400
+15% +$64.2K ﹤0.01% 1293
2022
Q2 		$392K Sell
16,500
-2,081
-11% -$45.3K ﹤0.01% 1331
2022
Q1 		$418K Buy
18,581
+6,726
+57% +$143K ﹤0.01% 1319
2021
Q4 		$235K Buy
+11,855
New +$240K ﹤0.01% 1339

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Natixis Advisors's CORT Position: Q2 2026 in Review

Natixis Advisors increased its Corcept Therapeutics (CORT) stake by 97% in Q2 2026, buying an estimated $1.49M and bringing the position to 50,392 shares worth $4.38M. The position accounts for ﹤0.01% of the portfolio, ranked #956.

Natixis Advisors first reported a position in CORT in Q4 2021 and has held it in 19 quarters since. The position peaked at $4.54M in Q1 2025. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Natixis Advisors held 50,392 shares of Corcept Therapeutics worth $4.38M as of Q2 2026.
  • Natixis Advisors bought 24,758 Corcept Therapeutics shares in Q2 2026, an estimated $1.49M.
  • Corcept Therapeutics made up ﹤0.01% of Natixis Advisors's portfolio in Q2 2026, its #956 holding.
  • Natixis Advisors first reported a position in Corcept Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Natixis Advisors's Corcept Therapeutics position peaked at $4.54M in Q1 2025.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.